The drug trastuzumab deruxtecan improves progression-free survival in HER2-positive breast cancer in 75.8% of patients. The results of the study, led by the International Breast Cancer Center and published in The New England Journal of Medicine, are “the most positive in history,” according to the authors.
–
Related posts:
RIVM: watch out when utilizing dietary dietary supplements containing Mucuna pruriens
The unexpected health consequence of always waking up early
Almost the same, recognize the different symptoms of the Singapore flu and chicken pox
Summary and contributions of CNR Health meetings in New Aquitaine in October/December 2022
:strip_icc():format(jpeg)/kly-media-production/medias/2841654/original/096329800_1561972203-tbc.jpg?resize=150%2C150&ssl=1 "Recognize Early, Here Are 5 Signs of Tuberculosis Lung Disease")
